Gastroenterology

Columbia China opens its third and largest hospital in Jiaxing, China

Saturday, October 23, 2021 - 9:11am

JIAXING, China, Oct. 23, 2021 /PRNewswire/ -- Columbia China, a joint venture between Seattle's Columbia Pacific Management, Sheares Healthcare Group, a 100% owned subsidiary of Singapore investment company Temasek, and Hong Kong-based conglomerate Swire Pacific Limited, opens its third & largest 500-bed multi-specialty hospital in Jiaxing, Zhejiang Province.

Key Points: 
  • JIAXING, China, Oct. 23, 2021 /PRNewswire/ -- Columbia China, a joint venture between Seattle's Columbia Pacific Management, Sheares Healthcare Group, a 100% owned subsidiary of Singapore investment company Temasek, and Hong Kong-based conglomerate Swire Pacific Limited, opens its third & largest 500-bed multi-specialty hospital in Jiaxing, Zhejiang Province.
  • The services provided at the Jiaxing Kaiyi Hospital include outpatient consultations, inpatient services, accident & emergency and health screening.
  • "With the opening of its third and largest hospital, Columbia China aims to deliver the highest level of healthcare quality, service and patient experience to the 5.5m population in Jiaxing," said Bee Lan Tan, President & Group CEO of Columbia China.
  • Columbia China is a privately-held Shanghai-based healthcare company jointly invested by Columbia Pacific Management (CPM) from the United States, Sheares Healthcare Group (SHEARES) from Singapore and Swire Pacific Limited from Hong Kong.

Columbia China opens its third and largest hospital in Jiaxing, China

Saturday, October 23, 2021 - 9:00am

JIAXING, China, Oct. 23, 2021 /PRNewswire/ -- Columbia China, a joint venture between Seattle's Columbia Pacific Management, Sheares Healthcare Group, a 100% owned subsidiary of Singapore investment company Temasek, and Hong Kong-based conglomerate Swire Pacific Limited, opens its third & largest 500-bed multi-specialty hospital in Jiaxing, Zhejiang Province.

Key Points: 
  • JIAXING, China, Oct. 23, 2021 /PRNewswire/ -- Columbia China, a joint venture between Seattle's Columbia Pacific Management, Sheares Healthcare Group, a 100% owned subsidiary of Singapore investment company Temasek, and Hong Kong-based conglomerate Swire Pacific Limited, opens its third & largest 500-bed multi-specialty hospital in Jiaxing, Zhejiang Province.
  • Jiaxing Kaiyi Hospital is licensed for 500 beds with a construction area of 112,000 square meters.
  • The services provided at the Jiaxing Kaiyi Hospital include outpatient consultations, inpatient services, accident & emergency and health screening.
  • "With the opening of its third and largest hospital, Columbia China aims to deliver the highest level of healthcare quality, service and patient experience to the 5.5m population in Jiaxing," said Bee Lan Tan, President & Group CEO of Columbia China.

Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers

Friday, October 22, 2021 - 10:30am

The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund.

Key Points: 
  • The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund.
  • The new capital will be used primarily to advance 2 leads assets into the clinic and further strengthen its internal drug pipeline.
  • The investor syndicate will join the Egle Therapeutics Board which will consist of Felice Verduyn-van Weegen (LSP), Vincent Brichard (LSP), Jean-Francois Morin (Bpifrance InnoBio 2) and Sacha Mann (Takeda Ventures).
  • Philippe Monteyne (Fund+), Jacques Mizrahi (Bioqube Ventures) and Elisa El Nouchi (Bpifrance InnoBio 2) will join as observers.

Acino acquires selected Aspen brands in South Africa

Friday, October 22, 2021 - 7:17am

The acquisition will further strengthen Acinos footprint in South Africa by expanding their offering in these important therapeutic segments.

Key Points: 
  • The acquisition will further strengthen Acinos footprint in South Africa by expanding their offering in these important therapeutic segments.
  • John Norman, Regional Director English-Speaking Africa at Acino said, I am very pleased to sign this agreement with Aspen.
  • The acquisition of these trusted brands in South Africa represents excellent scaling and commercial opportunities for Acino as it expands its footprint in South Africa by adding these products to its existing product portfolio.
  • For more information: www.acino.swiss
    Headquartered in Durban, South Africa, Aspen is a leading global specialty and branded multinational pharmaceutical company in both emerging and developed markets.

Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference

Thursday, October 21, 2021 - 5:01pm

Based on these results, S-217622 has the potential to reduce SARS-CoV-2 viral load with once-daily oral administration.

Key Points: 
  • Based on these results, S-217622 has the potential to reduce SARS-CoV-2 viral load with once-daily oral administration.
  • Shionogi is committed to Protect people worldwide from the threat of infectious diseases as our key focus.
  • S-217622, an investigational therapeutic antiviral drug for COVID-19, is a 3CL protease inhibitor created through joint research between Hokkaido University and Shionogi.
  • Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd. based in N.J. For more information on Shionogi Inc., please visit www.shionogi.com .

Fujifilm Exhibits Full Endoscopic and Endosurgical Portfolio at the American College of Gastroenterology Annual Scientific 2021 Meeting

Thursday, October 21, 2021 - 3:53pm

At the event, Fujifilm will showcase for the first time the G-EYE 700 Series Colonoscopes, now commercialized for use in the U.S.

Key Points: 
  • At the event, Fujifilm will showcase for the first time the G-EYE 700 Series Colonoscopes, now commercialized for use in the U.S.
  • This innovative technology was developed by Smart Medical Systems Ltd., and is distributed by Fujifilm.
  • G-EYE 700 Series Colonoscopes are designed to assist with visualization, stabilization and control during routine examinations.
  • The innovative design of the Fujifilm colonoscope is otherwise unchanged, and insertion can be performed as usual with the balloon deflated.

Micro-Tech Endoscopy Announces Enhanced EUS Needle

Thursday, October 21, 2021 - 2:00pm

ANN ARBOR, Mich., Oct. 21, 2021 /PRNewswire/ -- Micro-Tech Endoscopy launched an enhanced version of the company's EUS needles: Areus FNA and Trident FNB.

Key Points: 
  • ANN ARBOR, Mich., Oct. 21, 2021 /PRNewswire/ -- Micro-Tech Endoscopy launched an enhanced version of the company's EUS needles: Areus FNA and Trident FNB.
  • The updates include:
    Micro-Tech Endoscopy launched an enhanced version of the company's EUS needles: Areus FNA and Trident FNB.
  • Physicians and endoscopy departments need a clinically precise and cost-effective EUS needle, a tool that is critical in diagnostic and therapeutic intervention.
  • For more information about Micro-Tech Endoscopy, the improved EUS Needle or partnering with Micro-Tech on a device, visit mtendoscopy.com .

Bakar Labs Awards Deciduous Therapeutics and Rubik Therapeutics 2021 Golden Tickets

Thursday, October 21, 2021 - 1:00pm

BERKELEY, Calif., Oct. 21, 2021 /PRNewswire/ --Deciduous Therapeutics and Rubik Therapeutics have won 2021 Golden Tickets, granting the companies access to free lab space and facilities for a year, Bakar Labs announced today.

Key Points: 
  • BERKELEY, Calif., Oct. 21, 2021 /PRNewswire/ --Deciduous Therapeutics and Rubik Therapeutics have won 2021 Golden Tickets, granting the companies access to free lab space and facilities for a year, Bakar Labs announced today.
  • The Golden Tickets place Deciduous and Rubik in an exceptional environment where they can access resources on the Berkeley campus, interact with Bakar Labs' industry partners and members, and connect with up to 50 fellow resident startups.
  • "We're excited to receive the Golden Ticket and join the new life science entrepreneurship collective at Bakar Labs," said Robin Mansukhani, CEO of Deciduous.
  • "We are thrilled to have been selected for the Bakar Labs Golden Ticket sponsored by AbbVie," said Murray Robinson, CEO of Rubik.

Bausch Health Announces Tom Vadaketh Will Join Bausch Pharma* As Chief Financial Officer

Thursday, October 21, 2021 - 12:00pm

LAVAL, QC, Oct. 21, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Tom Vadaketh will join the Company as Chief Financial Officer (CFO) for its Bausch Pharma* business effective Jan. 3, 2022.

Key Points: 
  • LAVAL, QC, Oct. 21, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Tom Vadaketh will join the Company as Chief Financial Officer (CFO) for its Bausch Pharma* business effective Jan. 3, 2022.
  • "We are very pleased that Tom will join the leadership team of Bausch Pharma as our CFO.
  • "I am excited to join Bausch Pharma, which has a well-known reputation for trusted brands in health care," said Mr. Vadaketh.
  • *Bausch Health is referred to as "Bausch Pharma" and will assume a new name upon the separation of the company's eye health business, Bausch + Lomb.

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal

Thursday, October 21, 2021 - 12:00pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211021005526/en/
    Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal (Photo: Business Wire)
    The article includes highlights from Can-Fites Phase IIa NASH study of Namodenoson which achieved its study endpoints including significant anti-steatotic, anti-fibrotic, and anti-inflammatory effects.
  • Namodenoson is advancing into a Phase IIb NASH trial which is expected to commence patient enrollment in Q4 2021.
  • Principal Investigator of the Phase IIa study, Prof. Rifaat Safadi, commented, The acceptance and publication of the article presenting our Phase IIa results in this prestigious journal demonstrates the high value of the data and the potential of Namodenoson as safe and effective treatment for NASH.
  • As of 2016, NASH was the leading cause for liver transplants among women and the second leading cause for liver transplants overall.